Serum levels of specialised pro-resolving molecule pathways are greatly 1 2 increased in SARS-CoV-2 patients and correlate with markers of the adaptive immune response. 3 James Turnbull^{1,2,3,a}, Rakesh Jha^{1,2,a}, Catherine A. Ortori², Eleanor Lunt⁴, Patrick 4 5 J. Tighe³, William L. Irving^{1,3}, Sameer A. Gohir^{1,6}, Dong-Hyun Kim², Ana M. Valdes^{1,5,6}, Alexander W. Tarr^{1,3}, David A. Barrett^{1,2}, Victoria Chapman^{1,3,5}. 6 7 ¹ NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK 8 9 ² Centre for Analytical Bioscience, Advanced Materials and Healthcare 10 Technologies Division, School of Pharmacy, University of Nottingham, Nottingham, UK 11 ³ School of Life Sciences, Faculty of Medicine and Health Sciences, The University 12 13 of Nottingham, Nottingham, UK ⁴ Department of Health Care for Older People (HCOP), Queen's Medical Centre, 14 15 Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, 16 Nottinghamshire NG7 2UH, UK 17 ⁵ Pain Centre Versus Arthritis, University of Nottingham, Nottingham, UK ⁶ Academic Rheumatology, University of Nottingham, Nottingham, UK 18 19 ^a Joint First Author **Correspondence:** Professor Victoria Chapman, mbzvc@exmail.nottingham.ac.uk 20 21 Phone: +44 (0)115 82 30136 School of Life Sciences 22 23 University of Nottingham University Park 24 25 Nottingham NOF: DR Deprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 26

27 Abstract

28

29 Background

30 Specialised pro-resolution molecules (SPMs) halt the transition to chronic 31 pathogenic inflammation. We aimed to quantify serum levels of pro- and anti-32 inflammatory bioactive lipids in SARS-CoV-2 patients, and to identify potential 33 relationships with innate responses and clinical outcome.

34 Methods

Serum from 50 hospital admitted inpatients (22 female, 28 male) with confirmed symptomatic SARS-CoV-2 infection and 94 age and sex matched cohort collected prior to the pandemic, were processed for quantification of bioactive lipids. Antinucleocapsid and anti-spike quantitative binding assays were performed.

39 Results

40 SARS-CoV-2 serum had significantly higher concentrations of omega-6 derived pro-inflammatory lipids and omega-6 and omega-3 derived SPMs, compared to 41 age and sex matched controls. Levels of SPMs were not markedly altered by age. 42 There were significant positive correlations between SPMs and other bioactive 43 lipids and anti-spike antibody binding. Levels of some SPMs were significantly 44 45 higher in patients with an anti-spike antibody value >0.5. Levels of linoleic acid 5,6-dihydroxy-8Z,11Z,14Z-eicosatrienoic acid (5,6-DHET) were 46 (LA) and significantly lower in SARS-COV-2 patients who died. 47

48 Discussion

49 SARS-COV-2 infection was associated with a robust activation of the pathways 50 that generate the specialised pro-resolution molecules and other anti-

- 51 inflammatory bioactive lipids, supporting the future investigation of these
- 52 pathways which may inform the development of novel treatments.
- 53 Key words: SARS-CoV-2, specialised pro-resolving molecules, immune
- 54 response, bioactive lipids, anti-nucleocapsid

56 Introduction

57 Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterised by fever and cough, with more severe cases developing acute 58 respiratory distress, acute lung injury, pneumonia, and mortality[1-3]. The higher 59 rates of severe SARS-CoV-2 illness and death are associated with increasing 60 61 age[4, 5]. SARS-CoV-2 infection is associated with changes in adaptive and innate 62 immunity, including elevated levels of circulating neutrophils and the presence of peripherally derived macrophages in the lungs of severe cases[6, 7], reduced 63 numbers of circulating T cells[8] and robust cytokine responses, which continues 64 after clearance of the virus[9]. SARS-CoV-2 infection is associated with elevated 65 levels of pro-inflammatory cytokines, including IL6, IL1 β , and TNF α [10, 11], 66 however levels of anti-inflammatory cytokines IL4 and IL10 are also elevated [10]. 67 68 Knowledge of the impact of SARS-CoV-2 infection on the resolution of 69 inflammation pathways will provide crucial new mechanistic insight and potential new avenues for treatment[12-14]. 70

71 Prostaglandins (PGs) and leukotrienes have essential roles in initiating acute inflammatory responses and the generation of pro-inflammatory cytokines, which 72 73 sustain chronic inflammatory responses. In concert with these cyclooxygenase (COX) pathways, the lipoxygenase (LOX) pathways produce pro-inflammatory 74 hydroxyeicosatetraenoic acids (HETEs) from arachidonic acid (AA) and 75 hydroxyoctadecadienoic acids (HODEs) from di-homo-y-linolenic acid (LNA). The 76 77 active curtailing of inflammatory signalling is essential to restore tissue homeostasis and prevent chronic inflammatory events leading to pathology[15]. 78 Following the initial acute inflammatory phase, specialised pro-resolving molecules 79 (SPMs), derived from key polyunsaturated fatty acids (PUFAs), are generated and 80

81 orchestrate the resolution of inflammation by promoting macrophage mediated 82 clearance of cellular debris and counteracting the effects of pro-inflammatory 83 cytokines[15]. The SPMs are derived from omega-6 (ω -6) (LNA, AA) or omega-3 84 (ω -3) (eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)) substrates via 85 the COX, LOX and cytochrome P450 pathways[15] (SI Figure 1).

86 The most well characterised SPMs are the resolvins (Rvs), protectins (PDs), and 87 maresins (MaRs), which halt the transition from acute to chronic inflammation preventing pathogenesis[16]. 17(S)-hydroxy Docosahexaenoic acid (17-HDHA), a 88 substrate for the generation of the D series resolvins[15], enhances the adaptive 89 immune response in a preclinical model of influenza[17], both 17-HDHA and 90 resolvin D1 enhance B cell production and promote B cell differentiation towards 91 an antibody secreting phenotype[18]). The epoxyeicosatrienoic acids (EETs), 92 93 derived from AA via soluble epoxide hydrolase (sEH), also mediate resolution of 94 inflammation [19, 20], down-regulating inflammatory transcription factors such as NF-kB [21], curtailing the induction of COX2 and production of cytokines[22]. 95

96 Current knowledge of the consequences of SARS-CoV-2 infection on endogenous levels of SPMs and EETs is in its infancy. Building a comprehensive picture of the 97 impact of SARS-CoV-2 infection upon the serum lipidomic profile will aid 98 understanding of the therapeutic potential of resolution pathways for SARS-COV-99 100 2 infection[12, 13, 23]. Our aims were to 1) compare serum levels of a range of 101 SPMs and pro-inflammatory bioactive lipids between patients admitted to hospital 102 with SARS-CoV-2 infection and an age-matched control group, 2) determine the potential relationship between levels of these bioactive lipids and levels of anti-103 nucleocapsid and anti-spike antibody titre, markers of the production of an 104 105 adaptive immune response[24] and 3) investigate outcomes following infection.

106 Methods

107 Sample Collection and Preparation

108 Serum samples obtained from 50 inpatients admitted to Nottingham University Hospitals NHS Trust Queen's Medical Centre with symptomatic RT-PCR confirmed 109 SARS-CoV-2 infection were collected as diagnostic specimens for clinical chemistry 110 111 testing, excess sera were provided anonymously for research purposes. Review by the University of Nottingham's School of Life Sciences Ethical Review 112 Committee deemed the study to not require full ethical review. Approval for use 113 of anonymized clinical data was provided by the NHS Health Research Authority 114 (HRA) and Health and Care Research Wales (HCRW) (ref. 20/HRA/4843). Samples 115 116 were determined not to be Relevant Materials in line with the Human Tissue Authority. Risk assessments were approved by the UK Health and Safety Executive 117 118 (ref. CBA1.470.20.1). Serum samples were initially stored at 4°C for 24 h and 119 then inactivated with the WHO-approved protocol (4-hour room temperature incubation with 1% Triton X-100 in PBS) before analysis. Detailed methods on the 120 assessment of the potential effect of the viral deactivation protocol on serum lipid 121 levels are detailed in the supplementary information. Viral genomic sequencing 122 of samples from a subset of these patients was performed as part of the COG-UK 123 124 consortium[25].

Baseline serum samples from the iBEAT-OA cohort study (n=94) were used as age and sex matched controls[26], which were collected prior to the SARS-CoV-2 pandemic served as a SARS-CoV-2 negative control. As collected pre-pandemic a lack of SARS-CoV-2 infection was not confirmed. The iBEAT-OA cohort had a confirmed diagnosis of osteoarthritis. Ethical approval was obtained from the

130 Research Ethics Committee (ref: 18/EM/0154) and the Health Research Authority131 (protocol no: 18021).

132 Lipidomic Analysis

Serum bioactive lipids were extracted and measured using our published liquid chromatography-mass spectrometry (LC-MS/MS) quantification method for the major classes of pro- and anti-inflammatory lipid molecules, which has been updated to include SPMs and their precursor molecules[27]. 44 bioactive lipids were quantified, detailed methods are in Supplementary Information.

138 Anti-Nucleocapsid & Anti-Spike Binding Assays

Anti-nucleocapsid and anti-spike quantitative binding assays were performed on serum samples using ELISA following the protocol described by Tighe et al (2020)[24]. Levels of C reactive protein (CRP) were measured in clinical diagnostic tests (mean 172.9 levels ranged from 11-489). The median time between sample collection for CRP measurement and collection of serum for the measurement of bioactive lipids, anti-nucleocapsid and anti-spike antibody binding was 5 days.

145 Data Analysis

146 GraphPad Prism (Version 8.2.1) was used. In some cases, patients were stratified 147 into three age groups (<60, 61-74, & >75 years). Groups were assessed for normal distribution using D'Agostino & Pearson test and evaluated for significant 148 changes between groups using Kruskal-Wallis test with multiple comparisons 149 corrected for using Dunn's test. Multivariate analysis using Metaboanalyst 4.0 150 (https://www.metaboanalyst.ca/)[28] including principal component analysis 151 (PCA) was performed. Partial least square discrimination analysis (PLS-DA) was 152 153 used to identify the lipid mediator clusters. A cross validation analysis was used

to validate the PLS-DA model based on accuracy, R2 and Q2 scores and a
permutation test (SI Figure 3). Variable Importance in Projection (VIP) scores
greater than 1 were recognized as playing a key role in cluster differentiation (SI
Figure 4 & SI Table 1).

159 **Results**

160 **Characteristics of SARS-COV-2 infection cohort and clinical features**

Serum samples collected from hospital inpatients (22 female, 28 male) with confirmed diagnosis of Sars-CoV-2 (SARS-CoV-2) were studied (SI Table 2). 30 patients recovered and were discharged, 20 died, and 25 spent time in ICU during hospitalisation (SI Table 2).

165 SARS-COV-2 serum has a distinct bioactive lipid profile

166 SARS-CoV-2 serum had high concentrations of ω -6 derived pro-inflammatory lipids (Table 1) and ω -6 and ω -3 derived anti-inflammatory SPM lipids (Table 1), 167 which were significantly increased compared to age and sex matched control 168 serum. In control serum, comparable to the healthy population, many of the anti-169 170 inflammatory SPM lipids were not detectable, or present at very low levels[29]. PLS-DA analysis of these lipids identified contributors to the separation between 171 the SARS-CoV-2 and control serum (Figure 1A). 22 lipids from seven classes of 172 173 lipids had a VIP score >1 and statistically underpinned the separation between the two clusters (SI Figure 4A). Although serum concentrations of the PUFAs (LA, EPA 174 and DHA) were generally not different between the SARS-CoV-2 and control serum 175 (Figure 1B, SI Table 1), concentrations of the down-stream bioactive lipids were 176 177 markedly increased in SARS-CoV-2 serum (Figure 1B). There were substantially 178 higher levels of the pro-inflammatory molecule PGD2, and the anti-inflammatory SPMs (17-HDHA, RvD4, LXA4, LXA5), endocannabinoids (2-AG, AEA) and, 11,12-179 EET in SARS-CoV-2 serum, compared to control serum (Table 1, SI Table 3). Our 180 findings support a profound mobilisation of pro-resolving mediators following 181 SARS-CoV-2 infection. 182

PLS-DA analysis revealed a clear separation between the SARS-CoV-2 and control serum for the three age groups (SI Figure 2A-C). Overall, the majority of the lipids contributing to the separation between the SARS-CoV-2 and control serum were the same for the three age groups studied (SI Figure 2D). This was confirmed by a univariate analysis (Figure 2, SI Table 4). Overall, the ability to mount a pro-resolution response was not markedly altered by age in our study.

Changes in the flux through enzymatic pathways generating SPMs may provide insight into novel treatments for Sars-CoV-2 infection. Serum levels of DHA and the downstream metabolites, 17-HDHA and 14-HDHA, were correlated in both SARS-CoV-2 and control serum (Figure 3A-B). However, levels of EPA and 18-HEPE were correlated in SARS-CoV-2 serum but not control serum, suggesting a potential upregulation of the E series resolving pathway following infection (Figure 3C).

196 Serum levels of AA were within a healthy range in the control group[30], but were elevated in SARS-CoV-2 serum across all age groups (SI Figure 5A, Table 1). 197 Levels of the anti-inflammatory EETs and the downstream metabolites (DHETs) 198 are presented both individually and as a ratio to reflect the activity of the sEH 199 200 pathway (Table 1). The ratio of 11,12-EET:11,12-DHET was significantly increased in SARS-CoV-2 serum, compared to matched control serum (SI Figure 201 202 5B). There were some differences in the ratios of 8,9-EET:8,9-DHET and 14,15-203 EET:14,15-DHET but these were less consistent across the age groups for the two 204 groups (Table 1). In the SARS-CoV-2 serum, levels of AA were correlated with all 205 EETs, whereas in the control serum AA was only correlated with 8,9-EET and 11,12-EET (Figure 4B & 4C). These data suggest changes in the flux through the 206 sEH pathway following SARS-CoV-2 infection, worthy of further future 207 208 investigation.

209 Associations between adaptive immune responses to SARS-COV-2

210 infection and serum levels of bioactive lipids

211 Anti-SARS-CoV-2 antibody binding to the nucleocapsid protein was interrogated using a reference antigen. Viral sequence data, where available, confirmed that 212 the variants circulating in our cohort were either the Hu-1 strain, or the variant 213 defining the 20B lineage (defined by the spike D614G variant), with no variability 214 215 in nucleocapsid amino acid sequence[24]. There was a range of levels of anti-216 nucleocapsid (0.15 to 3.11 OD450) and anti-spike antibody (0.115-3.067 OD450) 217 in the SARS-CoV-2 group. Anti-nucleocapsid data (Table 2) are discussed in SI. Based on the range of anti-spike antibody binding, patients were separated into 218 219 two groups: low (<0.5, n=26) and high (>0.5, n=26), the subset of patients who died had significantly lower levels of anti-spike antibody binding (SI Figure 6). 220 Levels of 18-HEPE, 17-HDHA, RvD4 and 14,15-EET were significantly higher in 221 patients with an anti-spike antibody value >0.5 (Figure 5). There were statistically 222 223 significant positive correlations between these lipids and anti-spike antibody binding for the entire group of patients (Table 2). 224

225 Analysis of serum levels of bioactive lipids early in the infection and the clinical outcome identified that levels of LA and 5,6-DHET were significantly lower in 226 SARS-CoV-2 infected patients who died, and the ratio of 5,6-EET:5,6-DHET was 227 228 higher in those patients that died compared to those that survived (SI Table 5).

230 Discussion

231 SARS-CoV-2 infection was associated with robust increases in both ω -6 and ω -3 derived bioactive lipids which have well characterized roles in both pro- and anti-232 Significant increases in serum levels of pro-233 inflammatory responses[31]. 234 inflammatory lipids included PGE2, TBXB2 and LTB4 and a range of bioactive lipids 235 with well-established roles in dampening down / resolving inflammatory processes 236 were evident in the SARS-CoV-2 group, compared to the age matched control group. Of particular note was the 47-fold increase in levels of the SPM precursor 237 17-HDHA and the SPMs RvD4 and Mar2, serum levels of which are normally close 238 to, or below, the limits of detection in the healthy population[32]. Substantial 239 240 increases in levels of some EETs and endocannabinoids also support a concerted anti-inflammatory response via multiple enzymatic pathways following SARS-CoV-241 2 infection. Our demonstration of a robust activation of the resolution pathways 242 243 following SARS-CoV-2 infection, irrespective of patient age, points to a complex 244 pathophysiological response which may be amenable to pharmacological intervention and provide new targets for treatment. 245

There was a broad range of anti-nucleocapsid and anti-spike responses in the 246 SARS-CoV-2 group, indicative of adaptive immune response to infection. 247 Consistent with a larger study, increased anti-spike responses were associated 248 249 with improved clinical outcome [24]. SARS-CoV-2 patients with higher anti-spike 250 responses (>0.5) had significantly increased levels of a number anti-inflammatory and resolution molecules as well as some pro-inflammatory lipids. The statistically 251 altered bioactive lipids represent clusters of SPMs, lipoxins and EETs which either 252 253 directly mediate resolution of inflammation or are metabolites in the resolution pathways and are generated by COX, LOX and CYP pathways. Levels of PUFA 254 255 substrates were not substantially altered by SARS-CoV-2 infection or age, thus it 256 is unlikely that substrate and therefore diet is major determining factor in the 257 resolution response to SARS-CoV-2 infection. The strong correlations between 258 PUFAs and their downstream SPM pathway metabolites in the SARS-CoV-2 259 infection group suggests that these enzymatic pathways are upregulated by this infection, particularly evident for the E series pathway. Our findings support future 260 261 studies of the relationship between the antibody response to SARS-CoV-2 infection, activation of the resolution pathways and clinical outcome in a larger 262 263 cohort of patients.

264 Our findings are consistent with the recent report of up-regulation of plasma and 265 serum SPMs and increased expression of related enzymatic pathways in peripheral 266 blood monocyte subsets in 19 patients infected with SARS-CoV-2[33] and findings by Archambault et al (2020)[34]. In addition, increased levels of pro-267 inflammatory bioactive lipids and anti-inflammatory SPMs, including RvD4, D5, 268 D2, D1 and PDX have been reported in bronchoalveolar lavage from SARS-CoV-2 269 270 patient[35]. SPMs are already known to modulate acute lung injury and 271 respiratory distress syndrome[36], supporting these findings following SARS-CoV-2 infection. Antibodies generated by B cells are critical to anti-viral immunity. 272 The D series precursors and resolvins, including 17-HDHA, enhance human B cell 273 274 antibody production by promoting differentiation towards an anti-body secreting 275 phenotype[18]. In a pre-clinical murine model of influenza immunization, 17-HDHA treatment increased antigen specific antibody responses and protected 276 277 against live influenza virus infection [17]. These data suggest that a robust 278 generation of 17-HDHA following infection not only acts to counter pro-279 inflammatory responses but may also facilitate the response of B cells to mount an antibody response. To date there are no studies of the effects of the SPMs on 280 281 SARS-CoV-2 infection in patients, however, it has been reported that both RvD1

and RvD2 have beneficial effects on inflammatory responses in SARS-CoV-2infected macrophages[37].

284 Current evidence suggests that treatments for SARS-CoV-2 infection, alongside vaccinations, will remain a priority in the immediate future. Identification of the 285 critical steps involved in the up-regulation of these anti-inflammatory pathways 286 287 may be instructive for the development of interventions aimed at dampening the inflammatory response or promoting the clearance of the inflammation arising 288 289 from SARS-CoV-2 infection. Dexamethasone has been identified as an important treatment to promote recovery from SARS-CoV-2 infection. Dexamethasone has 290 been shown to increase SPM levels in a small number of SARS-CoV-2 infected 291 292 patients[33], healthy volunteers[38] and in allergic airway inflammation[39]. Future investigation of the potential contribution of SPMs to the beneficial effects 293 of dexamethasone in patients with SARS-CoV-2 infection in a larger cohort will 294 improve further our understanding of the potential mechanisms of action of this 295 treatment. 296

297 There are a number of study limitations. Serum samples were collected from 298 patients hospitalised with SARS-CoV-2 for clinical diagnostic tests during the first wave of the pandemic in the UK. Due to the clinical pressures within the system 299 at the time some clinical data, such as BMI, was not collected. It is known that 300 301 levels of SPMs are decreased with increased BMI, which could potentially contribute to SARS-CoV-2 related morbidities and mortalities[40]. Although we 302 303 have data relating to whether a patient was admitted to intensive care, clinical 304 decision making was related to multiple factors beyond the severity of the infection 305 and therefore further analysis of potential impact has not been performed. Serum samples were collected within the first few days of hospital admission and 306 represent a snapshot of the anti-nucleocapsid and anti-spike response and the 307

308 lipid levels at a point in time. It is important to note that levels of antibodies 309 change over time, however we do not have matched longitudinal data. The anti-310 nucleocapsid and anti-spike signal provides an indication of the potency of the adaptive immune response following infection. The viral genome sequencing data 311 available for these patients indicated that the nucleocapsid amino acid sequence 312 313 was completely conserved between infections. While it is possible that there may be mismatches between the antigen used in our assay and the strain of infecting 314 315 virus that mean that antibodies are present which are undetected by our assay, 316 at the time of sampling there was minimal genetic diversity in UK isolates[www.nextrstrain.org]. To mitigate against this, we used ELISAs against 317 318 two antigens.

In summary, our findings highlight that SARS-CoV-2 infection can lead to very 319 robust activation of the pathways that generate the specialised pro-resolving 320 molecules and other anti-inflammatory bioactive lipids. This new knowledge 321 322 supports the future investigation of these pathways which may inform the development of novel anti-inflammatory treatments for SARS-CoV-2 infection. 323 Furthermore, these new datasets provide us opportunities to explore further the 324 underlying molecular pathways that regulate the resolution pathways in humans, 325 with the goal of identifying novel approaches for the development of new 326 327 therapeutics for other infections and chronic inflammatory diseases.

329 Notes

330 Author Contributions:

- 331 VC, DAB, DHK, & AWT conceived the study, secured the funding, supervised data
- 332 collection and analysis, and prepared manuscript.
- 333 JT, RJ, & CO performed lipidomic analysis of samples.
- 334 AWT, PJT, & WLI supplied clinical samples, performed measurement of anti-
- 335 nucleocapsid and prepared manuscript.
- 336 AMV & SAG provided control serum samples.
- 337 JT & RJ performed statistical analysis and prepared manuscript.
- 338 EL provided clinical insight into data interpretation and prepared manuscript.
- 339 All authors reviewed manuscript and had final responsibility for the decision to

340 submit for publication.

341 Acknowledgements:

The authors thank Professors David Walsh and John Gladman for their advice in preparation of the manuscript. The authors also thank Dr Divyateja Hrushikesh and colleagues from the Queens Medical Centre for providing samples and clinical data.

346 **Disclaimer:**

347 The source of funding had no influence over the design or conduct of the study.

348 **Financial Support:**

- 349 This research was funded by the NIHR Nottingham Biomedical Research Centre.
- 350 The views expressed are those of the author(s) and not necessarily those of the
- 351 NHS, the NIHR or the Department of Health and Social Care.
- 352 **Potential conflicts of interest:** The authors declare no conflicts of interests.

395 References

396	1.	Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill
397		patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,
398		retrospective, observational study. The Lancet Respiratory Medicine
399		2020 ; 8(5): 475-81.
400	2.	Fan E, Beitler JR, Brochard L, et al. COVID-19-associated acute
401		respiratory distress syndrome: is a different approach to management
402		warranted? The Lancet Respiratory Medicine 2020; 8(8): 816-21.
403	3.	Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory
404		Distress Syndrome and Death in Patients With Coronavirus Disease 2019
405		Pneumonia in Wuhan, China. JAMA Intern Med 2020 ; 180(7): 934-43.
406	4.	Ho FK, Petermann-Rocha F, Gray SR, et al. Is older age associated with
407		COVID-19 mortality in the absence of other risk factors? General
408		population cohort study of 470,034 participants. PloS one 2020 ; 15(11):
409		e0241824-e.
410	5.	Jayaraj R, Kumarasamy C, Shetty SS, Ram M R, Shaw P. Clinical and
411		conceptual comments on "Risk factors of critical & mortal COVID-19
412		cases: A systematic literature review and meta-analysis". The Journal of
413		infection 2020 ; 81(4): 647-79.
414	6.	Merad M, Martin JC. Pathological inflammation in patients with COVID-19:
415		a key role for monocytes and macrophages. Nature reviews Immunology
416		2020 ; 20(6): 355-62.
417	7.	Zhand S, Saghaeian Jazi M, Mohammadi S, et al. COVID-19: The Immune
418		Responses and Clinical Therapy Candidates. International journal of
419		molecular sciences 2020 ; 21(15): 5559.

- 420 8. Kenneth ER, Monty M, David AS, et al. Severe immunosuppression and
- 421 not a cytokine storm characterizes COVID-19 infections. JCI insight **2021**;
 422 5(17).
- 423 9. Blanco-Melo D, Nilsson-Payant BE, Liu W-C, et al. Imbalanced Host
- 424 Response to SARS-CoV-2 Drives Development of COVID-19. Cell
- 425 (Cambridge) **2020**; 181(5): 1036-45.e9.
- 426 10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with
- 427 2019 novel coronavirus in Wuhan, China. The Lancet (British edition)
 428 2020; 395(10223): 497-506.
- 429 11. Karaba SM, Jones G, Helsel T, et al. Prevalence of Co-infection at the Time
 430 of Hospital Admission in COVID-19 Patients, A Multicenter Study. Open
- 431 forum infectious diseases **2021**; 8(1): ofaa578-ofaa.
- 432 12. Regidor P-A, Santos FG, Rizo JM, Egea FM. Pro resolving inflammatory
- 433 effects of the lipid mediators of omega 3 fatty acids and its implication in

434 SARS COVID-19. Medical hypotheses **2020**; 145: 110340-.

- 435 13. Panigrahy D, Gilligan MM, Huang S, et al. Inflammation resolution: a dual-
- 436 pronged approach to averting cytokine storms in COVID-19? Cancer and
 437 metastasis reviews **2020**; 39(2): 337-40.
- 438 14. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19:
- 439 The Current Evidence and Treatment Strategies. Frontiers in immunology
 440 **2020**; 11: 1708-.
- 441 15. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-
- resolving superfamily of mediators. The Journal of clinical investigation
- 443 **2018**; 128(7): 2657-69.

444	16.	Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous
445		regulators of infection and inflammation. Nature reviews Immunology
446		2016 ; 16(1): 51-67.
447	17.	Ramon S, Baker SF, Sahler JM, et al. The specialized proresolving
448		mediator 17-HDHA enhances the antibody-mediated immune response
449		against influenza virus: a new class of adjuvant? The Journal of
450		immunology (1950) 2014 ; 193(12): 6031-40.
451	18.	Ramon S, Gao F, Serhan CN, Phipps RP. Specialized proresolving
452		mediators enhance human B cell differentiation to antibody-secreting
453		cells. The Journal of immunology (1950) 2012 ; 189(2): 1036-42.
454	19.	Tam Vincent C, Quehenberger O, Oshansky Christine M, et al. Lipidomic
455		Profiling of Influenza Infection Identifies Mediators that Induce and
456		Resolve Inflammation. Cell (Cambridge) 2013 ; 154(1): 213-27.
457	20.	Romashko M, Schragenheim J, Abraham NG, McClung JA.
458		Epoxyeicosatrienoic Acid as Therapy for Diabetic and Ischemic
459		Cardiomyopathy. Trends in pharmacological sciences (Regular ed) 2016;
460		37(11): 945-62.
461	21.	Dong L, Dong L, Zhou Y, et al. Soluble Epoxide Hydrolase Inhibitor
462		Suppresses the Expression of Triggering Receptor Expressed on Myeloid
463		Cells-1 by Inhibiting NF-kB Activation in Murine Macrophage.
464		Inflammation 2017 ; 40(1): 13-20.
465	22.	Bora I, Steven LJ, Arzu U, et al. Soluble Epoxide Hydrolase and
466		Epoxyeicosatrienoic Acids Modulate Two Distinct Analgesic Pathways.
467		Proceedings of the National Academy of Sciences - PNAS 2008; 105(48):
468		18901-6.

	469	23.	Darwesh AM	, Bassiouni W	, Sosnowski D	, Seubert JM.	Can N-3
--	-----	-----	------------	---------------	---------------	---------------	---------

- 470 polyunsaturated fatty acids be considered a potential adjuvant therapy for
- 471 COVID-19-associated cardiovascular complications? Pharmacology &
- 472 therapeutics (Oxford) **2020**: 107703-.
- 473 24. Tighe PJ, Urbanowicz RA, Fairclough CL, et al. **2020**.
- 474 25. consortium TC-GUC-U. An integrated national scale SARS-CoV-2 genomic
- surveillance network. The Lancet Microbe **2020**; 1(3): e99-e100.
- 476 26. Gohir SA, Greenhaff P, Abhishek A, Valdes AM. Evaluating the efficacy of
- 477 Internet-Based Exercise programme Aimed at Treating knee Osteoarthritis
- 478 (iBEAT-OA) in the community: a study protocol for a randomised
- 479 controlled trial. BMJ open **2019**; 9(10): e030564-e.
- 480 27. Wong A, Sagar DR, Ortori CA, Kendall DA, Chapman V, Barrett DA.
- 481 Simultaneous tissue profiling of eicosanoid and endocannabinoid lipid
- families in a rat model of osteoarthritis. Journal of lipid research **2014**;
- 483 55(9): 1902-13.
- 484 28. Chong J, Xia J. Using MetaboAnalyst 4.0 for Metabolomics Data Analysis,
- 485 Interpretation, and Integration with Other Omics Data. Computational
 486 Methods and Data Analysis for Metabolomics **2020**; 2104: 337-60.
- 487 29. Norris PC, Skulas-Ray AC, Riley I, et al. Identification of specialized pro-
- resolving mediator clusters from healthy adults after intravenous low-dose
- 489 endotoxin and omega-3 supplementation: a methodological validation.
- 490 Scientific reports **2018**; 8(1): 18050-13.
- Abdelmagid SA, Clarke SE, Nielsen DE, et al. Correction: Comprehensive
 profiling of plasma fatty acid concentrations in young healthy Canadian
 adults. PloS one **2015**; 10(5): e0128167-e.

494	31.	Gilroy DW, Bishop-Bailey D. Lipid mediators in immune regulation and
495		resolution. British journal of pharmacology 2019 ; 176(8): 1009-23.
496	32.	Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. Identification and
497		signature profiles for pro-resolving and inflammatory lipid mediators in
498		human tissue. American Journal of Physiology: Cell Physiology 2014;
499		307(1): C39-C54.
500	33.	Koenis DS, Beegun I, Jouvene CC, et al. Disrupted Resolution Mechanisms
501		Favor Altered Phagocyte Responses in Covid-19. Circulation research
502		2021.
503	34.	Archambault AS, Zaid Y, Rakotoarivelo V, et al. High levels of eicosanoids
504		and docosanoids in the lungs of intubated COVID-19 patients. The FASEB
505		journal 2021 ; 35(6): e21666-n/a.
506	35.	Schwarz B, Sharma L, Roberts L, et al. Severe SARS-CoV-2 infection in
507		humans is defined by a shift in the serum lipidome resulting in
508		dysregulation of eicosanoid immune mediators. medRxiv 2020.
509	36.	Sandhaus S, Swick AG. Specialized proresolving mediators in infection and
510		lung injury. BioFactors (Oxford) 2021 ; 47(1): 6-18.
511	37.	Recchiuti A, Patruno S, Mattoscio D, et al. Resolvin D1 and D2 reduce
512		SARS-CoV-2-induced inflammatory responses in cystic fibrosis
513		macrophages. The FASEB journal 2021 ; 35(4): e21441-n/a.
514	38.	Barden A, Phillips M, Hill LM, et al. Antiemetic doses of dexamethasone
515		and their effects on immune cell populations and plasma mediators of
516		inflammation resolution in healthy volunteers. Prostaglandins,
517		leukotrienes and essential fatty acids 2018; 139: 31-9.
518	39.	Pyrillou K, Chairakaki A-D, Tamvakopoulos C, Andreakos E.
519		Dexamethasone induces ω 3-derived immunoresolvents driving resolution

520 of allergic airway inflammation. Journal of allergy and clinical immunology

521 **2018**; 142(2): 691-5.e4.

- 522 40. Pal A, Gowdy KM, Oestreich KJ, Beck M, Shaikh SR. Obesity-Driven
- 523 Deficiencies of Specialized Pro-resolving Mediators May Drive Adverse
- 524 Outcomes During SARS-CoV-2 Infection. Frontiers in immunology **2020**;
- 525 11: 1997.

526 Figure Legends:

Figure 1. A: Partial least square discrimination analysis (PLS-DA) for the 44 serum lipids quantified in SARS-CoV-2(n=50) and age and sex matched controls (n=94) with R2 = 0.944, Q2 = 0.932 and Accuracy = 1.0 B-I: Histograms of the highest ranked lipid mediators, PUFA (AA, LA, EPA, DHA), SPMs (17-HDHA, RvD4, LXA4, LXA5), PGD2, HETES (5-HETE, 9-HETE, 16-HETE, 19-HETE, 15-HETE), DiHETES (5, 15-DiHETEs, 8, 9-DiHETEs), 11,12-EET, DHETS (11, 12-DHET, 14, 15-DHET) and Endocannabinoids (2-AG, AEA).

Figure 2 Serum concentrations of (A) DHA, (B) 17-HDHA, (C) RvD4 (D) Maresin 2, and (E) 18-HEPE in SARS-CoV-2 (n=50) and age and sex matched control serum (n=94) stratified by age group. Groups were assessed for normal distribution using D'Agostino & Pearson test. Significance was assessed using Kruskal-Wallis test correcting for multiple comparisons using Dunn's test. *p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001.

Figure 3. Correlation analysis of DHA & EPA and relevant down-stream SPM pathway metabolites (A) 17-HDHA, (B) 14-HDHA, and (C) 18-HEPE in SARS-CoV-2 (n=50) and age and sex controls (n=94). Data analysed by Spearman's Rho.

Figure 4. Correlation analysis between AA and down-stream CYP450 metabolites (A) 5,6-EET, (B) 8,9-EET, (C)1,12-EET, and (D) 14,15-EET in SARS-CoV-2 and control groups. Data analysed by Spearman's Rho.

Figure 5. Serum concentration of significantly altered pro-resolution lipid mediators A) EPA, B) 18-HEPE, C) DHA, D) 17-HDHA, E) 14-HDHA, F) RvD4, G) Maresin 2, & H) 14,15-EET based on the anti-spike antibody response (low group <0.5, n=26, (high group>0.5, n=24) in SARS-CoV-2 patients. Groups were assessed for normal distribution using D'Agostino & Pearson test. Significance was assessed using Mann-Whitney test. *p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001.

554 Table 1. Concentrations of pro-inflammatory and anti-inflammatory bioactive lipids quantified in SARS-CoV-2 (n=50) and age and sex matched controls (n=94). 555 Statistical analysis by Mann-Whitney Test. Where lipids were not detected in 556 samples, an arbitrary value of 0.001 indicated by * was used for statistical 557 analysis. 558

Bioactive lipids			Mean Concentration				וM) ± S	P Value	
			C (ontr n=9	ol 4)	Sa	ars-COV (n=50)	-2	
AA		M SD)	47.98	±	12.75	99.61	±	60.21	<0.0001
LA		n ±)	307.8	±	109.7	213.79	±	108.4	< 0.001
5-HETE			0.99	±	0.40	158.33	Ŧ	159.17	< 0.0001
8-HETE			0.81	±	0.57	3.52	Ŧ	3.32	< 0.0001
9-HETE			0.15	±	0.05	16.27	Ŧ	19.02	< 0.0001
11-HETE			1.77	±	1.34	19.84	Ŧ	19.95	< 0.0001
12-HETE			C	0.001	*	162.41	±	137.29	< 0.0001
15-HETE	≥		7.14	±	4.79	135.18	±	125.42	< 0.0001
16-HETE	ato		0.20	±	0.05	0.22	±	0.08	0.4442
19-HETE	nm		0.37	±	0.29	188.65	Ŧ	199.17	< 0.0001
20-HETE	ıflaı	ŧSΓ	1.04	±	0.56	69.80	Ŧ	54.66	< 0.0001
ТВХВ2	o-ir	.) M	21.66	±	20.33	63.20	±	80.40	<0.0001
11-dihy-TBXB2	Ч	L L	1.10	±	1.47	0.29	±	0.33	0.0001
PGE2			0.37	±	0.33	0.56	±	0.41	0.0033
PGD2			0.001*		1.12	±	1.34	<0.0001	
LTB4			0.52	±	0.72	5.30	±	0.67	<0.0001
13-oxo-ODE			6.82	±	5.45	25.85	±	32.33	0.0001
9-oxo-ODE			0.85	±	0.96	7.51	±	10.28	<0.0001
9-HODE			6.14	±	3.03	225.74	±	308.14	<0.0001
13-HODE			12.44	±	5.72	263.98	±	363.04	<0.0001
DHA		M SD)	36.96	±	17.63	39.67	±	27.01	0.7135
EPA		n ±)	37.26	±	4.72	26.13	Ŧ	21.59	<0.001
17-HDHA	tory		1.88	±	1.46	88.61	Ŧ	107.3	<0.0001
14-HDHA	ma		55.53	±	54.4	93.11	±	69.82	0.0006
18-HEPE	am	SD)	0.49	±	0.32	10.27	±	14.16	< 0.0001
RvD4	-inf	5∓)	C	0.001	*	4.11	±	3.94	< 0.0001
Maresin 2	Anti	Ъц	0.03	±	0.01	0.42	±	0.48	< 0.0001
5,6-EET			0.24	±	0.38	0.30	±	0.29	< 0.0001
5,6-DHET			0.38	±	0.21	2.35	±	1.73	< 0.0001

5,6-Ratio		0.60	Ŧ	0.72	0.21	±	0.24	< 0.0001
8,9-EET		0.21	±	0.21	0.74	±	0.88	< 0.0001
8,9-DHET		0.22	±	0.07	0.47	±	0.32	< 0.0001
8,9-Ratio		0.97	Ŧ	0.86	2.63	±	4.09	0.0098
11,12-EET		0.56	±	0.77	160.95	±	122.47	< 0.0001
11,12-DHET		0.53	±	0.16	0.60	±	0.32	0.315
11,12-Ratio		1.09	±	1.31	363.01	±	407.70	< 0.0001
14,15-EET		0.27	Ŧ	0.35	0.43	±	0.44	< 0.0001
14,15-DHET		0.43	±	0.14	0.52	±	0.27	0.0672
14,15-Ratio		0.68	±	0.74	0.90	±	0.73	0.0002

561 Table 2. Correlation analysis between concentrations of bioactive lipid with antinucleocapsid & anti-spike antibody response in SARS-CoV-2 (n=50). Data 562 563 analysed by Spearman's Rho.

Bioactive lipids	Correlation Analysis of Lipids vs Antibody binding								
•	Anti-N	ucleocapsid	Anti-Spike						
-	R Value	P Value	R Value	P Value					
AA	0.326	0.021	0.352	0.012					
LA	0.249	0.081	0.382	0.006					
DHA	0.369	0.009	0.337	0.017					
EPA	0.419	0.002	0.540	<0.0001					
17-HDHA	0.269	0.059	0.537	<0.0001					
18-HEPE	0.366	0.009	0.410	0.003					
14-HDHA	0.434	0.002	0.293	0.039					
RvD4	0.211	0.142	0.449	0.001					
Maresin 2	0.282	0.055	0.343	0.018					
LXA4	0.051	0.723	0.324	0.022					
LXA5	0.222	0.133	0.436	0.002					
5-HETE	0.093	0.52	0.361	0.010					
8-HETE	0.404	0.004	0.419	0.002					
9-HETE	0.27	0.058	0.469	0.001					
11-HETE	0.279	0.05	0.464	0.001					
12-HETE	0.231	0.106	0.084	0.563					
15-HETE	0.259	0.069	0.407	0.003					
16-HETE	0.245	0.097	0.045	0.756					
19-HETE	0.138	0.344	0.314	0.028					
20-HETE	0.234	0.101	0.099	0.494					
ТВХВ2	-0.26	0.071	-0.052	0.722					
PGE2	0.049	0.744	0.275	0.056					
PGD2	0.113	0.445	0.283	0.052					
LTB4	-0.041	0.776	0.326	0.021					
5,6-EET	0.357	0.011	0.271	0.057					
5,6-DHET	0.024	0.867	0.310	0.029					
5,6-Ratio	0.243	0.089	-0.018	0.904					
8,9-EET	0.099	0.494	0.185	0.198					
8,9-DHET	0.063	0.663	-0.104	0.474					
8,9-Ratio	0.064	0.664	0.164	0.257					
11,12-EET	0.239	0.093	0.084	0.564					
11,12-DHET	0.109	0.452	-0.041	0.779					
11,12-Ratio	0.15	0.297	0.114	0.431					
14,15-EET	0.302	0.033	0.334	0.018					
14,15-DHET	0.023	0.874	-0.194	0.178					
14,15-Ratio	0.339	0.016	0.443	0.001					
13-oxo-ODE	0.202	0.169	0.447	0.002					
9-oxo-ODE	0.243	0.154	0.482	0.003					
9-HODE	0.265	0.063	0.505	0.0002					
13-HODE	0.268	0.059	0.488	0.0003					
AEA	0.017	0.907	-0.216	0.131					
PEA	-0.071	0.626	-0.083	0.567					
OEA	0.063	0.666	-0.060	0.679					

564

Figure 1. 566



Figure 2. 568



Figure 3. 570

Α



572 Figure 4.



**

RvD4

**

19

-

High Antis Po.51

High Anits (205)

Figure 5. 574



